AKT1 Gene

📖 Wiki Page

gene1373 wordssynced 2026-04-02

AKT1 — AKT Serine/Threonine Kinase 1

...

AKT1 — AKT Serine/Threonine Kinase 1

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">AKT1 Gene</th>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>14q32.33</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>207</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>164730</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000142208</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P31749</td>
</tr>
<tr>
<td class="label">Gene Length</td>
<td>~50 kb</td>
</tr>
<tr>
<td class="label">Exons</td>
<td>14 coding exons</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>480 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~56 kDa</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">GSK3β</td>
<td>Ser9 phosphorylation (inhibition)</td>
</tr>
<tr>
<td class="label">mTOR</td>
<td>Thr246 phosphorylation (activation)</td>
</tr>
<tr>
<td class="label">BAD</td>
<td>Ser136 phosphorylation (inhibition)</td>
</tr>
<tr>
<td class="label">FOXO1/3</td>
<td>Thr24/Ser32 phosphorylation (nuclear export)</td>
</tr>
<tr>
<td class="label">CREB</td>
<td>Ser133 phosphorylation (activation)</td>
</tr>
<tr>
<td class="label">NF-κB</td>
<td>IKK activation</td>
</tr>
<tr>
<td class="label">ASK1</td>
<td>Ser83 phosphorylation (inhibition)</td>
</tr>
<tr>
<td class="label">P21/P27</td>
<td>Phosphorylation (activation)</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression</td>
</tr>
<tr>
<td class="label">Brain (cortex)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Brain (hippocampus)</td>
<td>Very High</td>
</tr>
<tr>
<td class="label">Brain (cerebellum)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Substantia nigra</td>
<td>High</td>
</tr>
<tr>
<td class="label">Heart</td>
<td>High</td>
</tr>
<tr>
<td class="label">Muscle</td>
<td>High</td>
</tr>
<tr>
<td class="label">Pancreas</td>
<td>High</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">AKT1 activators</td>
<td>Small molecules enhancing AKT1 activity</td>
</tr>
<tr>
<td class="label">BDNF mimetics</td>
<td>Activate AKT1 pathway</td>
</tr>
<tr>
<td class="label">mTOR inhibitors</td>
<td>Paradoxically increase AKT1 via feedback</td>
</tr>
<tr>
<td class="label">GSK3β inhibitors</td>
<td>Downstream of AKT1</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Agent/Method</td>
</tr>
<tr>
<td class="label">AKT activators</td>
<td>Small molecules</td>
</tr>
<tr>
<td class="label">Growth factors</td>
<td>BDNF, IGF-1, GDNF</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV-AKT1</td>
</tr>
<tr>
<td class="label">Combination therapy</td>
<td>AKT1 + neurotrophic factors</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">Alzheimer's Disease</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">990 edges</a></td>
</tr>
</table>

Overview

AKT1 (AKT Serine/Threonine Kinase 1, also known as Protein Kinase B Alpha, PKBα) encodes a serine/threonine kinase that serves as a central node in the PI3K/AKT/mTOR signaling pathway. AKT1 is one of three AKT isoforms (AKT1, AKT2, AKT3) with overlapping but distinct functions in the nervous system. AKT1 plays critical roles in neuronal development, synaptic plasticity, mitochondrial function, and autophagy regulation, making it a key player in neurodegenerative disease pathogenesis. Dysregulation of AKT1 signaling is implicated in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), Huntington's disease, and ALS.

Gene Structure

Genomic Organization

Promoter and Regulation

The AKT1 promoter is regulated by multiple transcription factors including:

CREB: Activity-dependent AKT1 expression in neurons
NF-κB: Inflammatory regulation of AKT1
SP1: Basal expression in most tissues
Hypoxia-inducible factors (HIF): Regulation under hypoxic conditions

Protein Structure

Domain Architecture

AKT1 contains three functional domains:

PH domain (Pleckstrin Homology): N-terminal domain (aa 1-123) that binds PIP3 generated by PI3K, recruiting AKT1 to the plasma membrane[^1].

Kinase domain (aa 148-411): Contains the activation loop with Thr308 phosphorylation site, catalyzed by PDK1[^1].

C-terminal regulatory domain (aa 412-480): Contains Ser473 phosphorylation site, catalyzed by mTORC2[^1].

Activation Mechanism

AKT1 activation follows a well-characterized three-step process:

PIP3 recruitment: PI3K-generated PIP3 binds AKT1 PH domain, localizing it to the membrane

Thr308 phosphorylation: PDK1 phosphorylates Thr308 in the activation loop

Ser473 phosphorylation: mTORC2 phosphorylates Ser473 in the hydrophobic motif

Full AKT1 activation requires both phosphorylation events, resulting in a 100-fold increase in kinase activity.

Molecular Signaling

PI3K/AKT/mTOR Pathway

AKT1 sits at the crossroads of multiple signaling cascades:

Mermaid diagram (expand to render)

Key Downstream Targets

AKT1 phosphorylates over 100 substrates with diverse functions:

Expression Pattern

Tissue Distribution

AKT1 is widely expressed throughout the body and brain:

Cell Type Specificity

[Neurons](/entities/neurons): Strong expression in pyramidal neurons, medium spiny neurons
[Astrocytes](/entities/astrocytes): Moderate expression, supports neuronal survival
Oligodendrocytes: Present, regulates myelination
Microglia: Low expression under baseline conditions

Role in Neurodegeneration

Alzheimer's Disease

AKT1 Signaling in AD

AKT1 signaling is significantly impaired in Alzheimer's disease at multiple levels:

Reduced AKT1 activity: Postmortem AD brain shows decreased AKT1 phosphorylation at both Thr308 and Ser473[^2].

Growth factor signaling deficits: BDNF-mediated AKT1 activation is compromised in AD hippocampus[^2].

GSK3β dysregulation: Loss of AKT1-mediated GSK3β inhibition leads to increased tau hyperphosphorylation[^2].

Synaptic dysfunction: Impaired AKT1 signaling contributes to LTP deficits and memory impairment[^2].

Aβ interactions: Aβ oligomers disrupt AKT1 activation through multiple mechanisms including inhibition of PI3K[^2].

Therapeutic Implications

Parkinson's Disease

Neuroprotective Mechanisms

AKT1 provides critical neuroprotection in dopaminergic neurons:

Dopaminergic neuron survival: AKT1 protects against MPTP, 6-OHDA, and alpha-synuclein toxicity[^3].

LRRK2 interactions: LRRK2 mutations common in familial PD intersect with AKT1 signaling[^3].

PINK1/Parkin mitophagy: AKT1 regulates mitochondrial quality control pathways[^3].

Autophagy regulation: AKT1-mTORC1 axis controls autophagosome formation and clearance[^3].

Therapeutic Targeting

Growth factor delivery: GDNF and BDNF activate AKT1 in dopaminergic neurons
Small molecule AKT activators: Research stage, oncogenic risk limits development
Gene therapy: AAV-mediated AKT1 expression in development

Huntington's Disease

Mutant Huntingtin Effects

Mutant huntingtin protein impairs AKT1 signaling in multiple ways:

AKT1 activation reduction: mHTT disrupts PI3K/AKT1 signaling cascade[^4].

Neuroprotection loss: Loss of AKT1-mediated survival signaling contributes to neuronal death[^4].

Metabolic dysfunction: AKT1 regulates glucose metabolism disrupted in HD[^4].

Therapeutic restoration: AKT1 activation reduces mHTT toxicity in models[^4].

Amyotrophic Lateral Sclerosis (ALS)

Motor Neuron Vulnerability

AKT1 signaling is dysregulated in ALS:

Survival pathway deficits: Impaired AKT1 activity in motor neurons[^5].

TDP-43 pathology: TDP-43 aggregates affect AKT1 localization and function[^5].

Growth factor therapies: AKT1 pathway enhancement is a therapeutic strategy[^5].

Therapeutic Strategies

Current Approaches

Challenges

Oncogenic risk: Constitutively active AKT1 promotes cancer; therapeutic window is narrow
Isoform specificity: Pan-AKT inhibition affects all three isoforms with different consequences
Feedback loops: mTOR inhibition paradoxically increases AKT1 activity through feedback
BBB penetration: Most AKT inhibitors do not cross the blood-brain barrier

Animal Models

Knockout and Knock-in Models

AKT1 null mice: Perinatal lethality with growth deficiency and brain developmental abnormalities
Neuron-specific AKT1 mice: Show deficits in synaptic plasticity, learning, and memory
Constitutively active AKT1: Improves neuronal survival but promotes tumorigenesis
AKT1 S473A knockin: Shows importance of Ser473 phosphorylation for neuronal function

Disease Models

5xFAD mice: Show reduced AKT1 activity in hippocampus
MPTP/6-OHDA models: AKT1 activation is neuroprotective
N171-82Q HD mice: AKT1 activation reduces mutant huntingtin toxicity

Research Directions

Isoform-specific functions: Understanding AKT1 vs AKT2/AKT3 in different neuronal populations

Neuron-specific substrates: Identifying AKT1 substrates specific to neurons

Therapeutic window optimization: Balancing survival benefits with oncogenic risk

Biomarker development: AKT1 phosphorylation as a biomarker of disease progression

Combination approaches: AKT1 pathway enhancement with disease-specific targets

Interaction Network

Receptor Cross-talk

AKT1 interacts with multiple signaling pathways:

PI3K: Upstream activator of AKT1
mTORC1: Downstream target, with complex feedback
PTEN: Negative regulator (tumor suppressor)
PDK1: Kinase for Thr308 phosphorylation
mTORC2: Kinase for Ser473 phosphorylation

Protein Complexes

PI3K complex: AKT1 recruited to membrane by PIP3
mTORC2: AKT1 phosphorylation at Ser473
AKT1 substrate complexes: Multiple scaffolding proteins organize substrate specificity

References

[Manning BD, et al., AKT/PKB signaling: navigating the network (2023)](https://pubmed.ncbi.nlm.nih.gov/37595570/)

[Kerr F, et al., AKT signaling in Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/34974233/)

[Xu Q, et al., AKT and neurodegeneration in Parkinson's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34288541/)

[Colin E, et al., Huntingtin aggregation and neuroprotection by AKT (2023)](https://pubmed.ncbi.nlm.nih.gov/36748452/)

[Luo R, et al., AKT in ALS: pathogenetic mechanisms and therapeutic targets (2024)](https://pubmed.ncbi.nlm.nih.gov/38347622/)

[Bhattacharya K, et al., AKT1 in neuronal development and function (2023)](https://pubmed.ncbi.nlm.nih.gov/37098642/)

External Links

[NCBI Gene: AKT1](https://www.ncbi.nlm.nih.gov/gene/207)
[UniProt: AKT1](https://www.uniprot.org/uniprot/P31749)
[Human Protein Atlas: AKT1](https://www.proteinatlas.org/ENSG00000142208-AKT1)

Pathway Diagram

The following diagram shows the key molecular relationships involving AKT1 Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

AKT1 Gene

AKT1 — AKT Serine/Threonine Kinase 1

AKT1 — AKT Serine/Threonine Kinase 1

Overview

Gene Structure

Genomic Organization

Promoter and Regulation

Protein Structure

Domain Architecture

Activation Mechanism

Molecular Signaling

PI3K/AKT/mTOR Pathway

Key Downstream Targets

Expression Pattern

Tissue Distribution

Cell Type Specificity

Role in Neurodegeneration

Alzheimer's Disease

AKT1 Signaling in AD

Therapeutic Implications

Parkinson's Disease

Neuroprotective Mechanisms

Therapeutic Targeting

Huntington's Disease

Mutant Huntingtin Effects

Amyotrophic Lateral Sclerosis (ALS)

Motor Neuron Vulnerability

Therapeutic Strategies

Current Approaches

Challenges

Animal Models

Knockout and Knock-in Models

Disease Models

Research Directions

Interaction Network

Receptor Cross-talk

Protein Complexes

References

See Also

External Links

Pathway Diagram